Are Alivus Life Sciences Ltd latest results good or bad?

Alivus Life Sciences Ltd's latest financial results for Q4 FY26 present a mixed operational landscape. The company reported net sales of ₹689.12 crores, reflecting a sequential growth of 2.41% from the previous quarter and a year-on-year increase of 6.09%. This indicates that while the company is maintaining a positive sales trajectory, the growth rate has moderated compared to the previous quarter's robust performance. Net profit for the quarter reached ₹162.66 crores, marking an 8.26% sequential increase and a 14.66% rise year-on-year. This profit growth suggests that the company is effectively managing its bottom line, with the profit after tax margin improving to 23.60% from 22.33% in the previous quarter. However, this margin expansion was primarily driven by a reduction in the effective tax rate rather than operational efficiencies. A key concern arises from the operating margin, which contracted significantly from 34.37% in Q3 FY26 to 31.13% in Q4 FY26. This decline, amounting to a 324 basis point contraction, raises questions about the company's operational efficiency and ability to maintain pricing power in a competitive market. The increase in employee costs and the pressure from rising input costs appear to be contributing factors to this margin compression. For the full fiscal year FY26, Alivus Life Sciences achieved net sales of ₹2,551.84 crores and net profit of ₹564.49 crores, indicating year-on-year growth of 6.95% and 16.39%, respectively. The company's shareholding structure remains stable, with a promoter holding of 74.87% and a gradual increase in institutional participation, particularly from mutual funds. Overall, while Alivus Life Sciences demonstrates strong capital efficiency with a return on equity of 18.73% and a debt-free balance sheet, the recent trends in margin compression and decelerating revenue growth warrant careful monitoring. The company has seen an adjustment in its evaluation, reflecting the balance between its solid fundamentals and the challenges it faces in the current market environment.